Published in TB and Outbreaks Week, April 8th, 2003
"This discovery addresses a serious unmet need in health care," said Dr. Larry Zeitlin, Epicyte's lead scientist on the C. difficile project. "C. difficile infection is potentially fatal, and is very expensive to treat using current therapeutics. The Toxin B monoclonal antibody we have identified is the first monoclonal antibody from any source capable of neutralizing the toxin. Researchers have previously described Toxin A neutralizing monoclonals, but we...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.